Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ≥18 years of age.~* American Society of Anesthesiologists (ASA) physical status 1 or 2.~* Female subjects must be surgically sterile, at least 2 years postmenopausal, or using a medically acceptable method of birth control. If of childbearing potential, must have a documented negative pregnancy test within 24 hours before the first study drug administration.~* Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.~Exclusion Criteria:~* History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics.~* History of abnormal bleeding tendencies/clotting disorders.~* Regular use of anticoagulants (except for low dose aspirin for cardioprotection).~* Received any investigational drug within 30 days prior to study drug administration, and/or has planned administration of another investigational product or procedure during his/her participation in this study.~* Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.~* Subjects with significant medical conditions or laboratory results that, in the opinion of the Investigator, would constitute a contraindication to participation in the study, or cause inability to comply with the study requirements.~* Received bupivacaine or other local anesthetic within 7 days of first study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
- Cohort 2 (Type: ACTIVE_COMPARATOR): Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
- Cohort 3 (Type: ACTIVE_COMPARATOR): Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
- Cohort 4 (Type: ACTIVE_COMPARATOR): Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
- Cohort 5 (Type: ACTIVE_COMPARATOR): Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).

Based on this trial design, predict the completion outcome and termination type (if applicable).